This study is evaluating the safety and effectiveness of the D-KRd regimen (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in patients with multiple myeloma. The main outcome to be measured will be the number of patients who respond to treatment. This study is recruiting in Chicago, Illinois.
The details
Multiple myeloma (MM) is a type of cancer of the bone marrow that can lead to abnormal immune cells. Combination therapy is usually recommended for patients with newly diagnosed MM. It combines different types of treatment, such as chemotherapy and targeted therapy.
This study is evaluating the safety and effectiveness of the D-KRd regimen in patients with MM. The main outcome to be measured will be the number of patients who have a complete response (no signs of cancer) after treatment.
Who are they looking for?
This study is looking for 75 patients with newly diagnosed MM that has not been treated before. Patients who are not good candidates for a stem cell transplant can participate in this study. Patients should have normal blood test results and be willing to have a bone marrow sample taken at study entry. All patients must agree to use contraception during and 30 to 90 days after finishing the study.
Patients who have had major surgery within 3 weeks of study entry cannot participate. Patients who have had a heart attack within 6 months of study entry cannot participate. Patients with uncontrolled persistent asthma or obstructive lung disease, high blood pressure, or diabetes cannot participate. Patients with infections requiring treatment within 2 weeks of study entry cannot participate. Women who are pregnant or breastfeeding cannot participate.
How will it work
All patients will receive 8 cycles of D-KRd. Patients will be followed-up for up to 2 years.
The main outcome to be measured will be the number of patients who have no signs of cancer at 8 months after treatment. The number of patients who show no signs of disease over 2 years will also be determined. The number of patients who survive for 2 years without tumor growth or spread will also be determined. The number of patients who experience side effects from treatment will also be measured.
